Following the success of the first iCDP summit last year, we are returning this September to provide the primary industry platform for the advancement of cannabinoid-derived pharmaceuticals. When this summit takes place it will have been just over a year since GW Pharmaceutical's created the first FDA approved drug containing a cannabinoid API, and several contenders are hot on their heels. However, there are many challenges still obstructing the development of this generation of cannabinoid pharmaceuticals.
Join your peers at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit to solve your challenges in this fast growing field, and to maximise the potential of the next-generation of cannabinoid pharmaceuticals.
*Early booking and group discounts are available upon request. For more details visit our website for the full pricing list.
Conference + 2 Workshops: USD 3097.0,
Conference + 1 Workshops: USD 2598.0,
Conference Only: USD 2099.0,
Workshops Only: USD 599.0
Speakers: Guy Chamberland, Chief Executive Officer, Tetra Biopharma, Dennis Ahern, Vice President, Global Regulatory Affairs, Greenwich Biosciences, Mara Gordon, Founder & Director, Zelda Therapeutics, Brian Murphy, Chief Executive Officer, Emerald Biopharma, Sara Ward, Researcher, Oncology, Temple University, Ethan Russo, Professor, International Cannabis and Cannabinoids Institute, Andrea Small-Howard, Chief Science Officer, GB Sciences, Robert Walsh, Chief of Regulatory Affairs Branch Division of Therapeutics & Medical Consequences of Drug Abuse,NIDA, Sagnik Bhattacharyya, Reader of Translational Neuroscience & Psychiatry, King's College London